Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Systemic Lupus Erythematosus: HELP
Articles by Radboud J. E. M. Dolhain
Based on 4 articles published since 2010
(Why 4 articles?)
||||

Between 2010 and 2020, R. Dolhain wrote the following 4 articles about Lupus Erythematosus, Systemic.
 
+ Citations + Abstracts
1 Review State of the art: Reproduction and pregnancy in rheumatic diseases. 2015

Østensen, Monika / Andreoli, Laura / Brucato, Antonio / Cetin, Irene / Chambers, Christina / Clowse, Megan E B / Costedoat-Chalumeau, Nathalie / Cutolo, Maurizio / Dolhain, Radboud / Fenstad, M H / Förger, Frauke / Wahren-Herlenius, Marie / Ruiz-Irastorza, Guillermo / Koksvik, Hege / Nelson-Piercy, Catherine / Shoenfeld, Yehuda / Tincani, Angela / Villiger, Peter M / Wallenius, Marianne / von Wolff, Michael. ·National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, St. Olavs Hospital, University Hospital of Trondheim, Norway. Electronic address: monika.ostensen@gmail.com. · Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Italy. · Department of Internal Medicine, Ospedale papa Giovanni XXIII Bergamo, Italy. · Department of Mother and Child, Hospital Luigi Sacco, University of Milano, Italy. · Department of Pediatrics, University of California San Diego, La Jolla, CA 92093-0828, USA. · Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, USA. · Université Paris-Descartes, Paris, France; AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, Service de médecine interne, Paris, France. · Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy. · Department of Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. · Department of Immunology and Transfusion Medicine, St. Olavs Hospital, Trondheim, Norway. · Department of Rheumatology and Clinical Immunology/Allergology, University Hospital of Bern, CH-3010 Bern, Switzerland. · Department of Medicine, Centre for Molecular Medicine, Karolinska Universitetssjukhuset, Stockholm, Sweden. · Autoimmune Diseases Research Unit, Department of Internal Medicine, Biocruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain. · National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, St. Olavs Hospital, University Hospital of Trondheim, Norway. · Women's Health Academic Centre, St Thomas' Hospital, London, UK. · Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Israel. · Department of Rheumatology and Clinical Immunology, Ospedale Civile and University of Brescia, Brescia, Italy. · Department of Rheumatology and Clinical Immunology/Allergology, University Hospital of Bern, Bern, Switzerland. · National Service for Pregnancy and Rheumatic Diseases, Department of Rheumatology, Trondheim University Hospital, Trondheim, Norway; Dept of Neuroscience, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. · University Women's Hospital, Division of Gynaecological Endocrinology and Reproductive Medicine, University of Berne, Berne, Switzerland. ·Autoimmun Rev · Pubmed #25555818.

ABSTRACT: Throughout the last decade, increasing awareness has been raised on issues related to reproduction in rheumatic diseases including basic research to clarify the important role of estrogens in the etiology and pathophysiology of immune/inflammatory diseases. Sub- or infertility is a heterogeneous condition that can be related to immunological mechanisms, to pregnancy loss, to disease burden, to therapy, and to choices in regard to family size. Progress in reproductive medicine has made it possible for more patients with rheumatic disease to have children. Active disease in women with rheumatoid arthritis (RA) affects their children's birth weight and may have long-term effects on their future health status. Pregnancy complications as preeclampsia and intrauterine growth restriction are still increased in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), however, biomarkers can monitor adverse events, and several new therapies may improve outcomes. Pregnancies in women with APS remain a challenge, and better therapies for the obstetric APS are needed. New prospective studies indicate improved outcomes for pregnancies in women with rare diseases like systemic sclerosis and vasculitis. TNF inhibitors hold promise for maintaining remission in rheumatological patients and may be continued at least in the first half of pregnancy. Pre-conceptional counseling and interdisciplinary management of pregnancies are essential for ensuring optimal pregnancy outcomes.

2 Article Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. 2019

Groot, N / Shaikhani, D / Teng, Y K O / de Leeuw, K / Bijl, M / Dolhain, R J E M / Zirkzee, E / Fritsch-Stork, R / Bultink, I E M / Kamphuis, S. ·Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands, and Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands. · Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands. · Leiden University Medical Center, Leiden, The Netherlands. · University Medical Center, Groningen, The Netherlands. · Martini Hospital, Groningen, The Netherlands. · Erasmus University Medical Center, Rotterdam, The Netherlands. · Maasstad Hospital, Rotterdam, The Netherlands. · University Medical Center, Utrecht, The Netherlands, Hanusch Hospital of WGKK and AUVA Trauma Center, Vienna, Austria, and Sigmund Freud University, Vienna, Austria. · Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. ·Arthritis Rheumatol · Pubmed #30152151.

ABSTRACT: OBJECTIVE: Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease. Long-term outcome data are limited. This study was undertaken to identify clinical characteristics and health-related quality of life (HRQoL) of adults with childhood-onset SLE. METHODS: Patients participated in a single study visit comprising a structured history and physical examination. Disease activity (scored using the SLE Disease Activity Index 2000 [SLEDAI-2K]), damage (scored using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and HRQoL (scored using the Short Form 36 Health Survey) were assessed. Medical records were reviewed. RESULTS: In total, 111 childhood-onset SLE patients were included; the median disease duration was 20 years, 91% of patients were female, and 72% were white. Disease activity was low (median SLEDAI-2K score 4), and 71% of patients received prednisone, hydroxychloroquine (HCQ), and/or other disease-modifying antirheumatic drugs. The vast majority of new childhood-onset SLE-related manifestations developed within 2 years of diagnosis. Damage such as myocardial infarctions began occurring after 5 years. Most patients (62%) experienced damage, predominantly in the musculoskeletal, neuropsychiatric, and renal systems. Cerebrovascular accidents, renal transplants, replacement arthroplasties, and myocardial infarctions typically occurred at a young age (median age 20 years, 24 years, 34 years, and 39 years, respectively). Multivariate logistic regression analysis showed that damage accrual was associated with disease duration (odds ratio [OR] 1.15, P < 0.001), antiphospholipid antibody positivity (OR 3.56, P = 0.026), and hypertension (OR 3.21, P = 0.043). Current HCQ monotherapy was associated with an SDI score of 0 (OR 0.16, P = 0.009). In this cohort, HRQoL was impaired compared to the overall Dutch population. The presence of damage reduced HRQoL scores in 1 domain. High disease activity (SLEDAI-2K score ≥8) and changes in physical appearance strongly reduced HRQoL scores (in 4 of 8 domains and 7 of 8 domains, respectively). CONCLUSION: The majority of adults with childhood-onset SLE in this large cohort developed significant damage at a young age and had impaired HRQoL without achieving drug-free remission, illustrating the substantial impact of childhood-onset SLE on future life.

3 Article T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus? 2014

Brkic, Zana / Corneth, Odilia B J / van Helden-Meeuwsen, Cornelia G / Dolhain, Radboud J E M / Maria, Naomi I / Paulissen, Sandra M J / Davelaar, Nadine / van Hamburg, Jan Piet / van Daele, Paul L / Dalm, Virgil A / van Hagen, P Martin / Hazes, Johanna M W / Versnel, Marjan A / Lubberts, Erik. · ·Arthritis Res Ther · Pubmed #24598455.

ABSTRACT: INTRODUCTION: A hallmark of systemic autoimmune diseases like systemic lupus erythematosus (SLE) is the increased expression of interferon (IFN) type I inducible genes, so-called IFN type I signature. Recently, T-helper 17 subset (Th17 cells), which produces IL-17A, IL-17F, IL-21, and IL-22, has been implicated in SLE. As CCR6 enriches for Th17 cells, we used this approach to investigate whether CCR6⁺ memory T-helper cells producing IL-17A, IL-17F, IL-21, and/or IL-22 are increased in SLE patients and whether this increase is related to the presence of IFN type I signature. METHODS: In total, 25 SLE patients and 15 healthy controls (HCs) were included. SLE patients were divided into IFN type I signature-positive (IFN⁺) (n = 16) and negative (IFN⁻) (n = 9) patients, as assessed by mRNA expression of IFN-inducible genes (IFIGs) in monocytes. Expression of IL-17A, IL-17F, IL-21, and IL-22 by CD4⁺CD45RO⁺CCR6⁺ T cells (CCR6⁺ cells) was measured with flow cytometry and compared between IFN⁺, IFN⁻ patients and HCs. RESULTS: Increased percentages of IL-17A and IL-17A/IL-17F double-producing CCR6⁺ cells were observed in IFN⁺ patients compared with IFN⁻ patients and HCs. IL-17A and IL-17F expression within CCR6⁺ cells correlated significantly with IFIG expression. In addition, we found significant correlation between B-cell activating factor of the tumor necrosis family (BAFF)-a factor strongly correlating with IFN type I - and IL-21 producing CCR6⁺ cells. CONCLUSIONS: We show for the first time higher percentages of IL-17A and IL-17A/IL-17F double-producing CCR6⁺ memory T-helper cells in IFN⁺ SLE patients, supporting the hypothesis that IFN type I co-acts with Th17 cytokines in SLE pathogenesis.

4 Article Complicated systemic lupus erythematosus pancreatitis: pseudocyst, pseudoaneurysm, but real bleeding. 2011

Hoorn, E J / Flink, H J / Kuipers, E J / Poley, J-W / Mensink, P B F / Dolhain, R J E M. ·Departments of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. ejhoorn@gmail.com ·Lupus · Pubmed #20956462.

ABSTRACT: We report the case of a 25-year-old patient with systemic lupus erythematosus (SLE) pancreatitis which was complicated by pseudocyst and pseudoaneurysm formation. The pseudoaneurysm progressed to intra-abdominal bleeding requiring endovascular coil embolization of the gastroduodenal artery. The pseudocyst and hematoma formed two large abdominal fluid collections causing symptoms due to a mass effect. These fluid collections were treated conservatively, while active SLE was treated with steroids, azathioprine, and immunoglobulins. She finally made a full recovery. To the best of our knowledge, this is the first report of a bleeding pseudoaneurysm complicating SLE pancreatitis. Although anecdotal, this case may serve as a useful example of the possible complications of SLE pancreatitis, including considerations on optimal management.